These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36327902)

  • 1. Accurate diagnosis of prostate cancer with CRISPR-based nucleic acid test strip by simultaneously identifying PCA3 and KLK3 genes.
    Chen W; Wu S; Li G; Duan X; Sun X; Li S; Zhao Y; Gu D; Zeng G; Liu H
    Biosens Bioelectron; 2023 Jan; 220():114854. PubMed ID: 36327902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
    Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
    PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.
    Dijkstra S; Leyten GH; Jannink SA; de Jong H; Mulders PF; van Oort IM; Schalken JA
    Prostate; 2014 Sep; 74(12):1222-30. PubMed ID: 25043536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.
    Mao Z; Ji A; Yang K; He W; Hu Y; Zhang Q; Zhang D; Xie L
    Medicine (Baltimore); 2018 Oct; 97(42):e12806. PubMed ID: 30334974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis.
    Neves AF; Dias-Oliveira JD; Araújo TG; Marangoni K; Goulart LR
    Clin Chem Lab Med; 2013 Apr; 51(4):881-7. PubMed ID: 23241599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.
    Groskopf J; Aubin SM; Deras IL; Blase A; Bodrug S; Clark C; Brentano S; Mathis J; Pham J; Meyer T; Cass M; Hodge P; Macairan ML; Marks LS; Rittenhouse H
    Clin Chem; 2006 Jun; 52(6):1089-95. PubMed ID: 16627561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous noninvasive ultrasensitive detection of prostate specific antigen and lncRNA PCA3 using multiplexed dual optical microfibers with strong plasmonic nanointerfaces.
    Li H; Wang X; Wu H; Wang W; Zheng A; Zhu J; Liang L; Sun H; Lu L; Lv J; Yu Q; Wang H; Yu B
    Biosens Bioelectron; 2024 Nov; 264():116672. PubMed ID: 39151263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Milillo A; Papotti M; Porpiglia F
    BJU Int; 2014 Dec; 114(6b):E56-E61. PubMed ID: 24472071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual electrochemical genosensor for early diagnosis of prostate cancer through lncRNAs detection.
    Sánchez-Salcedo R; Miranda-Castro R; de-Los-Santos-Álvarez N; Lobo-Castañón MJ
    Biosens Bioelectron; 2021 Nov; 192():113520. PubMed ID: 34311209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals.
    Moradi Sardareh H; Goodarzi MT; Yadegar-Azari R; Poorolajal J; Mousavi-Bahar SH; Saidijam M
    Urol J; 2014 Nov; 11(6):1952-8. PubMed ID: 25433473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.